population, effective prognostic tools are needed to adequately capture and monitor CVD risk. Estimating disease-specific lipid modifications may add value for CVD risk assessment.
Oxidized LDL (low-density lipoprotein; oxLDL) significantly contributes to atherosclerosis propagation and remains an important target for treatment of CVD. 4, 5 Based on the structural and functional similarities between Lp(a) (lipoprotein [a] ) and LDL, the former has gained traction as a more reliable marker for CVD processes related to aging, including aortic stenosis. 6 However, lack of commercially available diagnostic tools for estimating oxidized Lp(a) (oxLp [a] ) and oxidized HDL (oxHDL) has significantly hindered the availability of data for more intense investigation. Limited studies using highly sensitive liquid chromatography tandem mass spectrometry, oxidized phospholipids contained within Lp(a) have been shown to augment the proinflammatory response and promote CVD progression-an effect that was attenuated with inactivation of oxidized phospholipids. 7 Additionally, lower oxHDL also had proatherosclerotic effects and was accompanied by significant immunologic responses. 8 On the contrary, emerging data suggest that low concentrations of oxidized phospholipids transported by oxLDL, oxLp(a), and oxHDL can confer more homeostatic than proinflammatory effects. Downstream signaling of PLs and its oxidized counterparts involves completely separate pathways and is dependent on their overall and relative concentrations within the circulation secondary to the disease state. 9 Moreover, it has been shown that patients with psoriasis have decreased cholesterol efflux capacity, 2 which in a single small study showed changes in phospholipid content of HDL composition after psoriasis treatment. Additionally, biologically active oxidized lipid mediators (LMs) derived from arachidonic and linoleic acids are esterified in cholesterol ester and PL transported by oxLDL and oxHDL. 10, 11 These LMs are highly abundant in psoriasis skin and play critical role in processes of inflammation initiation and resolution. 12 A recent study showed that lower oxHDL levels were associated with higher CVD risk in young, healthy population. 13 Another contributing factor to the reported HDL abnormalities may, in part, be because of low antioxidative properties as of PON-1 (paraoxonase-1) enzyme activity. 14, 15 However, most of the studies have reported ambiguous data on the PON-1 enzyme activity and need further analysis and clarification.
Coronary computed tomographic angiography (CCTA) provides a noninvasive imaging measurement of coronary plaque parameters and its respective subcomponents, including both dense-calcified plaque burden (DCB) and noncalcified plaque burden (NCB). 16 These CCTA-derived coronary plaque parameters have been used as a reliable predictor of future cardiovascular events. 17 Considering that traditional lipid parameters may not be adequately affected by psoriasis disease processes and related treatments, 18 we hypothesized that oxidation-modified lipoproteins might serve as a promising 
Novelty and Significance
What Is Known?
• Oxidation of lipoproteins, specifically LDL (low-density lipoprotein), is closely linked to development of atherosclerosis.
• Inflammation contributes to the initiation and propagation of oxidation.
• Psoriasis is a chronic inflammatory skin disease associated with increased oxidative stress and atherosclerosis.
What New Information Does This Article Contribute?
• Oxidation-modified lipids, including oxidized LDL and oxidized HDL (high-density lipoprotein), were significantly elevated in psoriasis.
• Oxidation-modified lipids were differentially associated with coronary plaque burden when stratified by psoriasis disease severity beyond traditional risk factors; this relationship was not captured by traditional lipids.
• Biological therapy for psoriasis was associated with a reduction in oxidized HDL and with a concomitant decrease in noncalcified burden at 1 year.
Psoriasis adds a cumulative risk to early cardiovascular disease development in a relatively young population by affecting lipoprotein function and coronary plaque composition. Limited prognostic value of traditional lipid parameters in psoriasis subjects warrants search for novel diagnostic markers for cardiovascular disease. Considering that lipid oxidation leads to proinflammatory and proatherosclerotic gain of function-we hypothesized that psoriasis-a systemic chronic inflammatory state with impaired oxidation-might significantly contribute to this process. We found that oxidation-modified lipoproteins, specifically oxidized LDL and oxidized HDL, differentially associated with lipidrich plaque based on psoriasis severity. Furthermore, patients with psoriasis on treatment notably had reduction in oxidized HDL, which was associated with an improvement in lipid-rich plaque.
Future investigation characterizing precise function of these oxidation-modified lipids may provide promising diagnostic platforms for effective cardiovascular disease management in psoriasis. November 9, 2018 tool for early heart disease detection and evaluation by CCTA. Indeed, the low antioxidative state of patients with psoriasis and high circulating levels of oxidation-modified LMs, 12 along with an increase in high-risk lipid-rich coronary plaque as assessed by NCB, 19 may provide a window to investigate and understand these associations in CVD.
Methods
The data that support the findings of this study are available to qualified researchers trained in human subject confidentiality protocols from the corresponding author on reasonable request.
All the enrolled 245 consecutive subjects with psoriasis were part of an ongoing National Institutes of Health cohort study (Figure) . A detailed description of methods and materials, including inclusion/exclusion criteria, clinical assessment, detailed imaging procedures, and statistical analyses for both the cohorts, is available in the Online Data Supplement. STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines were followed for reporting the findings from both the stages.
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Results
Study Population
Psoriasis subjects (n=232) were middle aged (mean [SD] 
Characterization of Oxidation-Modified Lipoproteins in Psoriasis
Oxidized LDL Although oxLDL levels at baseline were nonsignificantly higher in the psoriasis group (Table 1) , they were positively associated with some of the known CVD parameters, including hyperlipidemia, body mass index, and Framingham risk score (Table 2 ). Further analysis of CCTA-derived plaque parameters with traditional lipids (Table 3 ) and advance lipid phenotype showed significant positive association between NCB and ox-LDL (β=0.10; P=0.02; Tables 4 through 6), which remained significant beyond adjustment for traditional cardiovascular risk factors, lipid-lowering therapy, and systemic or biologic psoriasis therapy (β=0.12; P=0.006; Table 7 ). NMR lipid analysis showed predominant contribution of small LDL particles to the observed oxLDL association (Table 4) , whereas ApoB did not show significant contribution (Table 5 ). To determine whether skin disease severity affected these relationships, we stratified by disease severity and found disparate findings. Severe patients had a strong negative correlation between oxLDL and DCB, whereas mild psoriasis severity showed even stronger positive correlation with NCB and total burden (TB; Table 8 ).
Oxidized HDL oxHDL baseline levels were significantly higher in the psoriasis group compared with HV (mean [SD], 202.89±175.62 versus 176.88±216.25; P=0.02; Table 1 ). In contrast to oxLDL, oxHDL had a significant negative association with most of the CVD parameters (Table 2 ). TB and NCB had significant negative association with HDL-C (Table 3 ) and oxHDL (β=−0.12; P=0.007; Table 6 ). Such association remained significant beyond traditional cardiovascular risk factors, lipid-lowering therapy, and systemic or biologic psoriasis therapy (β=−0.12; P=0.006; Table 7 ). NMR lipid analysis showed predominant role of large HDL particles and inverse association with small LDL particles to the observed oxHDL associations ( along with significant ApoA1 (apolipoprotein A1) contribution. Of note, the same stratification approach of the psoriasis group for different skin disease severity revealed opposite correlation for NCB and DCB compared with oxLDL (Table 8) . More severe (PASI>10) patients had strong positive correlation of oxHDL with DCB, whereas moderate (PASI<10) psoriasis severity showed negative correlation with NCB and TB.
Oxidized LDL(a) and Lp(a) Both lipid parameters were significantly elevated in psoriasis group compared with HVs at baseline ( Table 1) . Strong positive association was observed for Lp(a) with age, female sex, hyperlipidemia, and glucose (Table 2 ). However, no significant association was observed for coronary plaque burden parameters (Tables 3 through 6 ). Further adjustment for conventional risk factors did not reveal any significant associations either (Table 7) . Lp(a) was mainly associated with small vldl (very low-density lipoprotein) particles, whereas oxLp(a) was negatively associated with large ldl particles (Table 4) . Notably, further stratification of psoriasis group for different psoriasis severity showed significant positive correlation of oxLp(a) with TB and NCB in patients with less-severe disease and negative for NCB in patients with severe psoriasis. In contrary, stratification for Lp(a) did not reveal any significant correlation (Table 8) .
PON-1 Activities and Its Relation to OxidationModified Lipids in Patients With Psoriasis
The PON-1 system determines HDL antioxidative properties in vivo and contributes to the CVD risk. 21 To address the potential variation in the PON-1 activities and clarity of measurements, we included additional psoriasis subjects (Online Table I ) from our general cohort with serum samples stored for ≤2 years maximum. This group consisted of 40 middle-aged individuals (mean [SD] age, 50.45 [13. 02] years), predominantly men (n=24; 60%), and a median PASI score of 7.9 (IQR, 3.4-11.0). Overall, this additional group did not differ significantly from the main cohort. Psoriasis subjects had significantly higher paraoxonase activity compared with HV (8.55±3.21 versus 6.24±3.82; P=0.01). However, arylesterase activity had a lower trend in psoriasis compared with HV, and lactonase activity did not differ between psoriasis and HV group (Online Table I ).
Association of Psoriasis Treatment With OxidationModified Lipoproteins
Patients with psoriasis stratified by systemic or biologic agents at baseline showed a positive association between oxLDL and both TB and NCB and a negative association between oxLDL and DCB (Table 8) . Furthermore, per our protocol, patients with moderate-severe psoriasis who start a new biologic during the study period (biologic naive) are seen 3 to 5 months after therapy. In this group, (Table 9 ) patients were middle aged (mean [SD] age, 46.7 [13.29] years), predominantly men (55%), and at low cardiovascular risk by Framingham risk score (median, 2.4; IQR, 1-2), with treatment consisting of anti-TNF (tumor necrosis factor; n=8; 40%), anti-IL (interleukin)-17 (n=7; 35%) and anti-IL-2/23 (n=5; 25%) therapy. At 3-to 5-month follow-up, we observed a statistically significant increase in TG along with increasing trend in Lp(a) 
Discussion
In our study investigating the relationship between OMLs (oxidation-modified lipids) and coronary plaque by CCTA in psoriasis, we demonstrate (1) psoriasis was associated with increased levels of many OMLs as compared with HVs; (2) whereas oxLDL was directly associated with NCB, oxHDL was inversely associated with both total and noncalcified coronary plaque; and (3) treatment of psoriasis with anti-inflammatory biologic therapy reduced oxHDL concurrent with a decrease in NCB at 1 year. Collectively, these findings suggest that circulating OML levels may be a useful marker of early atherosclerosis by CCTA in psoriasis.
Psoriasis-Associated CVD
Psoriasis-a chronic inflammatory skin disease-is associated with heightened risk for myocardial infarction in young psoriasis patients, translating to roughly 5 years of life lost. 22, 23 Moreover, dyslipidemia is one of the most prevalent comorbidities in psoriatic patients. 24 CCTA is a reliable, noninvasive imaging technique that allows for quantification and characterization of total and noncalcified coronary plaque. Prior work has demonstrated that TB and NCB predict prospective CV events in patients without inflammatory condition. 25, 26 Psoriasis is associated with higher noncalcified plaque in the coronary arteries-a finding shown to be reduced by anti-inflammatory treatment 19 in a small observational study. Because noncalcified coronary plaque is most often the culprit lesion in myocardial infarction, we used CCTA-derived plaque indices to understand the epidemiological association between NCB and oxidized lipids for early characterization of subclinical atherosclerosis.
Significant lipid composition and function disturbances associate with immunologic abnormalities in psoriasis.
2,27-29 Results reported as standardized β-coefficient (P values). HbA1C indicates hemoglobin A1C; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); OxHDL, oxidized high-density lipoprotein; OxLDL, oxidized low-density lipoprotein; OxLp(a), oxidized lipoprotein(a); and PASI, psoriasis area severity index. Most notably, the chronic, systemic inflammation of psoriasis is associated with altered HDL function. Beyond reverse cholesterol transport, HDL with its antioxidative, anti-inflammatory, antiapoptotic, and antithrombotic functions contribute considerably to mitigate atherosclerosis. 30 Systemic and vascular inflammation, however, has been proposed to convert HDL to a dysfunctional form and impair these protective properties, in effect promoting CVD. 31 Patients with psoriasis have a more atherogenic lipoprotein profile and decreased HDL efflux capacity. 32 Furthermore, inflammatory mediators, including adipocyte-derived cytokines, such as TNF-α, IL-6, and leptin, are known to induce dyslipidemia. These derangements may, in part, help explain the accumulated evidence of an epidemiological association between psoriasis and CVD. As such, psoriasis provides a useful model to understand the close relationships between lipoprotein dysfunction and early subclinical coronary atherosclerosis assessed by CCTA.
OML in Cardiovascular Disease
Psoriasis-related inflammation and oxidative stress are associated with higher lipoprotein oxidation, dyslipidemia, and CVD progression, even when LDL has been treated to target levels. 33, 34 Collectively, OMLs are critical to atherosclerosis progression because they are involved in foam cell generation, endothelial and smooth muscle cell dysfunction, 35, 36 and other inflammatory reactions, including subendothelial activation and vascular inflammation. 37 Furthermore, circulating OMLs are associated with subclinical atherosclerosis, as well as hard cardiovascular events. 38, 39 Most phases of atherosclerosis are driven by the inflammatory cascade. It is well known that oxidation of LDL initiates cascade of biochemical reactions leading to endothelial cell dysfunction and atherosclerotic plaque formation, 4 explaining the association between early plaque and oxLDL. In vitro experiments have shown low doses of oxLDL to be sufficient enough to activate macrophages and mast cells and synergistically increase monocyte-endothelium adhesion, whereas higher doses of oxLDL had less profound effect. 40 Thus, the reported immunologic activation by oxLDL contributes to endothelial dysfunction and early atherogenesis, dependent on the chronicity/severity of the underlying inflammatory milieu.
OMLs and Noncalcified Coronary Plaque in Psoriasis
In our study, patients with psoriasis had significantly higher levels of oxHDL and oxLp(a) compared with HVs. oxLDL also trended but was not statistically significant. Moreover, we demonstrated a bidirectional association between each oxidation-modified lipoprotein class and NCB, when stratified by psoriasis disease severity. 11 Furthermore, oxLDL showed strong positive correlation with NCB and TB even after adjusting for multiple cardiovascular risk factors. Oxidative modification of LDL is one of the earliest events in the pathogenesis of atherosclerosis, subsequently promoting an inflammatory environment and lipid deposition in the arterial wall. We confirm this association in a cohort of patients with psoriasis, similar to the previously reported associations in general population. Although Lp(a) is considered to be a more sensitive alternative to LDL in estimating cardiovascular risk and has been shown to mediate myocardial infarction, stroke, and peripheral arterial disease, 6 its role in chronic inflammatory disease states needs further exploration. Although we present an association between oxLp(a) and NCB, further mechanistic studies need to elucidate the impact of oxidation of Lp(a) and subsequently its role in propagating the lipid-rich noncalcified plaque.
Although research on OMLs has primarily focused on LDL, other plasma lipoproteins are also susceptible to Results reported as standardized β-coefficient (P values). DCB indicates dense-calcified burden; l_hdl_p, large HDL particle; l_ldl_p, large LDL particle; lm_vldl_p, large medium very LDL particle; NCB, noncalcified burden; s_hdl_p, small HDL particle; s_ldl_p, small LDL particle; s_vldl_p, small very LDL particle; and TB, total burden. Results reported as standardized β-coefficient (P values). ApoA1 indicates apolipoprotein A1; ApoB, apolipoprotein B; CEC, cholesterol efflux capacity; DCB, dense-calcified burden; Lp(a), lipoprotein(a); NCB, noncalcified burden; and TB, total burden. Results reported as standardized β-coefficient (P values). DCB indicates dense-calcified burden; NCB, noncalcified burden; OxHDL, oxidized highdensity lipoprotein; OxLDL, oxidized low-density lipoprotein; OxLp(a), oxidized lipoprotein(a); and TB, total burden. November 9, 2018 oxidative modification. In recent years, oxHDL has gained interest in pathogenesis of atherosclerosis, especially with advancement in our understanding of the various pathways that lead to HDL oxidation and affect its role of reverse cholesterol transport. oxHDL contribution to atherosclerosis has been postulated to be in an opposite way as oxLDL, 13 possibly because of the HDL proteome shifting to a proinflammatory, oxidative phenotype during psoriasis progression. This may be mediated through oxidative and immune-driven derangements of ApoA1, resulting in reduced HDL efflux and complete or partial loss of HDL's anti-inflammatory functions. Taken together, this is consistent with our finding that patients with severe psoriasis had strong positive correlation of oxH-DL with DCB, while mild-moderate severity showed negative correlation with NCB and TB.
Another possible explanation of the observed findings might be related to different concentrations of bioactive LMs within local tissues and the systemic circulation. Psoriasis skin and peripheral blood represent a diverse source of bioactive LMs, which have potent effects on inflammation progression and resolution. Specifically, psoriasis lesional skin is abundant in oxidized LMs 12 derived from arachidonic and linoleic acids, which predominantly have dietary source. Importantly, the main cargo of these oxidized LMs in circulation is LDL. Results reported as standardized β value (P values). BMI indicates body mass index; DCB, dense-calcified burden; FRS, Framingham risk score; Lp(a), lipoprotein(a); NCB, noncalcified burden; OxHDL, oxidized high-density lipoprotein; OxLDL, oxidized low-density lipoprotein; OxLp(a), oxidized lipoprotein(a); and TB, total burden.
The excess amount of these LMs in psoriasis inflamed skin requires high concentrations of LDL and a compensatory increase in HDL. These could be susceptible to increased oxidation in psoriasis disease partly explained by linoleic acidderived oxidized bioactive LMs, which are also highly present on the oxHDL and explicit protective function. 11 Furthermore, oxidation products of these polyunsaturated fatty acids esterified into cholesteryl esters and phospholipids affect TLR (toll-like receptor) 4 and the NLRP3 (NLR family pyrin domain-containing 3) inflammasome pathways, which possess multiple important biological functions. 9 Hence, investigation of mechanisms affecting function of these oxidized products is promising and deserves further investigation. 41 Our finding of increased oxHDL in patients with psoriasis might be attributable to the PON-1 function. PON-1 is an enzyme bound to HDL that is one of many important determinants of the antioxidative properties of HDL and may serve as a marker of CVD progression. Low PON-1 activity has been associated with worse prognosis for CVD. 42 In our study, patients with psoriasis had significantly higher PON-1 activity in comparison with healthy controls, likely a compensatory increase in response to greater oxHDL burden. Despite observing higher PON-1 activity in the psoriasis subgroup, it is plausible that it may represent a dysfunctional, noncardioprotective form. Finally, the bidirectionality in OML association with NCB could be a contingency in the face of chronicity of underlying low-grade inflammation in patients with psoriasis.
Reduction in OML Concurrent With a Decrease in NCB After Biological Therapy for Psoriasis
We followed a subset of patients with moderate-severe psoriasis never treated with a biologic (biologic naive) to Data represented as mean±SE or median (IQR) for parametric and nonparametric variables, respectively, and as n (%) for categorical variables. P values were derived from a single unpaired Student t test for parametric variables and Mann-Whitney U test for nonparametric variables. Pearson correlation coefficients represented as ρ-values (P values). Correlation results reported as standardized β-coefficient (P values). PASI: <3, mild; 3-10, moderate; >10, severe. DCB indicates dense-calcified burden; IQR, interquartile range; Lp(a), lipoprotein(a); NCB, noncalcified burden; OxHDL, oxidized high-density lipoprotein; OxLDL, oxidized low-density lipoprotein; OxLp(a), oxidized lipoprotein(a); PASI, psoriasis area severity index; and TB, total burden. November 9, 2018 understand how modulation of skin inflammation with biologic treatment may affect OMLs and NCB. Psoriasis treatment significantly decreased inflammatory response and restored HDL function independent of lipid levels. 18 As anticipated, oxHDL levels decreased after treatment, and ox-LDL trended toward a decrease. The differential, and more significant, treatment effects on oxHDL may be explained by its heterogeneity and relative ease of alteration of its dysfunctional form with abrogation of systemic inflammation. The detected increase in plasma TG and Lp(a) levels early on during treatment (3-5-month follow-up) may be because of a higher hepatic conversion of free fatty acids into TG. However, to what extent this observation relates to psoriasisspecific treatment or depicts the natural history of the disease needs future investigation. Furthermore, patients with psoriasis on treatment were noted to have an improvement in NCB at 1-year follow-up, independent of traditional cardiovascular risk, validating previous work. 43 The reduction in OMLs concurrent with reduction in NCB warrants careful in vitro follow-up studies to understand whether these are direct effects or operating through other complementary pathways.
Given the association between plasma markers of lipoprotein oxidation and incidence of atherosclerotic disease in chronic inflammatory states, it may be of clinical utility to investigate these markers in the early cardiovascular risk assessment of patients with chronic inflammatory disease and to assess efficacy of antipsoriatic/anti-inflammatory interventions. Furthermore, future research should attempt to expound the impact of different biologic therapies on these cardiovascular biomarkers with longer duration follow-ups. Considering the impact of lifestyle modifications and intensive statin-based regimen on polyunsaturated fatty acids oxidized products, the role of OML needs to be more deeply explored in reducing residual CVD risk in psoriatic patients over time. Finally, trials with deep characterization of lipoproteins concurrent with imaging-based assessment of early atherosclerosis (eg, noncalcified coronary plaque or vascular inflammation) should examine the comprehensive effect of biologic therapies on these lipoprotein biomarkers and whether there is subsequent effect on subclinical atherosclerosis.
Strengths and Limitations
To our knowledge, this is the first study to associate coronary plaque burden in psoriasis with OMLs. Longitudinal examination during 1 year demonstrated that improvement in skin disease was associated with an improvement in OML fraction and NCB. These findings are of interest because they suggest that OML and NCB may improve with adequate antipsoriasis therapy.
Our study is limited by small sample size and follow-up data and did not have randomized treatment allocation. Given the observational study design, we cannot exclude the possibility of residual confounding and are unable to derive any causal inference. Furthermore, our study relied on a surrogate marker of coronary artery disease through CCTA as the primary outcome instead of hard CV events; however, this was consistent with our intent to understand the natural course before CV events. When characterizing lipoproteins and CVD, sources of bias include age, sex, hypertensive status, dyslipidemia status, smoking status, and medical treatments. In our multivariable variables to understand the relationship between OMLs and coronary artery disease, we adjusted for these factors to attempt to understand whether an independent relationship existed between each OML and Data represented as mean±SD or median (IQR) for parametric and nonparametric variables, respectively, and as n (%) for categorical variables. P values were derived from a paired t test for parametric variables and the Wilcoxon signed-rank test for nonparametric variables. The McNemar test was used for categorical variables. P <0.05 was considered statistically significant. ApoA1 indicates apolipoprotein A1; ApoB, apolipoprotein B; DCB, densecalcified burden; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); NA, not available; NCB, noncalcified burden; OxHDL, oxidized high-density lipoprotein; OxLDL, oxidized low-density lipoprotein; OxLp(a), oxidized lipoprotein(a); and PASI, psoriasis area severity index. coronary artery disease. Furthermore, there are sources of bias that were not measured in our study and, therefore, not adjusted for in our models. These include dietary intake of specific foods, as well as detailed exercise frequency, as well as some psoriasis-specific features, which may be prone to recall bias (eg, onset of psoriasis, which permits psoriasis disease duration calculation). Lastly, investigating OMLs and CCTA results from healthy individuals without psoriasis and those with CVD is of great interest and should be a topic of future study in this field.
Conclusions
In conclusion, we demonstrated that the OMLs were increased in psoriasis and were differentially associated with coronary plaque burden, especially NCB, by psoriasis severity. Furthermore, we also demonstrated that anti-inflammatory treatment of psoriasis with biologic agents led to reduction in OMLs with a reduction in lipid-rich plaque as assessed by NCB. Collectively, we demonstrated the use of OMLs and its association with early subclinical atherosclerosis in coronary arteries. As such, future larger studies should confirm these findings and assess whether various biologic treatments lead to mitigation of early CVD and favorable modulation of OMLs.
